Phosphodiesterase 7(PDE7): A unique drug target for central nervous system diseases

Neuropharmacology. 2021 Sep 15:196:108694. doi: 10.1016/j.neuropharm.2021.108694. Epub 2021 Jul 7.

Abstract

Phosphodiesterase 7 (PDE7), one of the 11 phosphodiesterase (PDE) families, specifically hydrolyzes cyclic 3', 5'-adenosine monophosphate (cAMP). PDE7 is involved in many important functional processes in physiology and pathology by regulating intracellular cAMP signaling. Studies have demonstrated that PDE7 is widely expressed in the central nervous system (CNS) and potentially related to pathogenesis of many CNS diseases. Here, we summarized the classification and distribution of PDE7 in the brain and its functional roles in the mediation of CNS diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), multiple sclerosis (MS), and schizophrenia. It is expected that the findings collected here will not only lead to a better understanding of the mechanisms by which PDE7 mediates CNS function and diseases, but also aid in the development of novel drugs targeting PDE7 for treatment of CNS diseases.

Keywords: (AD); (PD); (PDE7); (cAMP); Alzheimer's disease; PDE7 inhibitor;Parkinson's disease; Phosphodiesterase 7; yclic adenosine monophosphate.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / metabolism*
  • Animals
  • Brain / metabolism*
  • Cyclic Nucleotide Phosphodiesterases, Type 7 / antagonists & inhibitors
  • Cyclic Nucleotide Phosphodiesterases, Type 7 / genetics
  • Cyclic Nucleotide Phosphodiesterases, Type 7 / metabolism*
  • Humans
  • Molecular Targeted Therapy
  • Multiple Sclerosis / drug therapy
  • Multiple Sclerosis / metabolism*
  • Parkinson Disease / drug therapy
  • Parkinson Disease / metabolism*
  • Phosphodiesterase Inhibitors / therapeutic use
  • Protein Isoforms
  • Schizophrenia / metabolism*

Substances

  • Phosphodiesterase Inhibitors
  • Protein Isoforms
  • Cyclic Nucleotide Phosphodiesterases, Type 7